- Wildfire Survivors Still Struggle With Basic Needs and Support
- Trump Administration Plans Deep Cuts to Federal Health Budget
- Top NIH Nutrition Researcher Quits, Citing Censorship Under Kennedy
- HHS Fires Team That Sets Federal Poverty Guidelines
- First Weight-Loss Pill From Lilly Shows Promising Results
- Allergy Expert Gives Tips On Seasonal Allergies
- Pregnancy Complications Affect Future Heart Health
- Stroke Among Younger Adults Linked To Non-Traditional Risks
- Psoriatic Arthritis Diagnoses Are Lagging, Patients Undertreated
- Magnetic Stimulation Aids Speech Recovery Following Stroke
Movantik Approved for Constipation From Opioids

Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.
Opioids are powerful painkillers that commonly cause constipation. Movantik’s safety and effectiveness to treat the problem were evaluated in two clinical studies involving 1,352 people who had taken opioids for at least four weeks for non-cancer related pain.
The most common side effects of Movantik were abdominal pain, diarrhea, headache and excessive gas, the FDA said in a news release.
Manufacturer AstraZeneca will be required to do an additional study to further evaluate the drug’s cardiovascular safety, the agency added.
AstraZeneca is based in Wilmington, Del.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.